Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Atheroprotective effects of methotrexate via the inhibition of YAP/TAZ under disturbed flow.

Liu D, Lv H, Liu Q, Sun Y, Hou S, Zhang L, Yang M, Han B, Wang G, Wang X, Du W, Nie H, Zhang R, Huang X, Hou J, Yu B.

J Transl Med. 2019 Nov 15;17(1):378. doi: 10.1186/s12967-019-02135-8.

2.

Integrin-YAP/TAZ-JNK cascade mediates atheroprotective effect of unidirectional shear flow.

Wang L, Luo JY, Li B, Tian XY, Chen LJ, Huang Y, Liu J, Deng D, Lau CW, Wan S, Ai D, Mak KK, Tong KK, Kwan KM, Wang N, Chiu JJ, Zhu Y, Huang Y.

Nature. 2016 Dec 22;540(7634):579-582. doi: 10.1038/nature20602. Epub 2016 Dec 7.

PMID:
27926730
3.

Arterial Wall Stress Induces Phenotypic Switching of Arterial Smooth Muscle Cells in Vascular Remodeling by Activating the YAP/TAZ Signaling Pathway.

Wang Y, Cao W, Cui J, Yu Y, Zhao Y, Shi J, Wu J, Xia Z, Yu B, Liu J.

Cell Physiol Biochem. 2018;51(2):842-853. doi: 10.1159/000495376. Epub 2018 Nov 22.

4.

Flow-dependent YAP/TAZ activities regulate endothelial phenotypes and atherosclerosis.

Wang KC, Yeh YT, Nguyen P, Limqueco E, Lopez J, Thorossian S, Guan KL, Li YJ, Chien S.

Proc Natl Acad Sci U S A. 2016 Oct 11;113(41):11525-11530. Epub 2016 Sep 26.

5.

Methotrexate-mediated activation of an AMPK-CREB-dependent pathway: a novel mechanism for vascular protection in chronic systemic inflammation.

Thornton CC, Al-Rashed F, Calay D, Birdsey GM, Bauer A, Mylroie H, Morley BJ, Randi AM, Haskard DO, Boyle JJ, Mason JC.

Ann Rheum Dis. 2016 Feb;75(2):439-48. doi: 10.1136/annrheumdis-2014-206305. Epub 2015 Jan 9.

6.

Cysteine S-Glutathionylation Promotes Stability and Activation of the Hippo Downstream Effector Transcriptional Co-activator with PDZ-binding Motif (TAZ).

Gandhirajan RK, Jain M, Walla B, Johnsen M, Bartram MP, Huynh Anh M, Rinschen MM, Benzing T, Schermer B.

J Biol Chem. 2016 May 27;291(22):11596-607. doi: 10.1074/jbc.M115.712539. Epub 2016 Apr 5.

7.

Hippo-YAP/TAZ signalling in organ regeneration and regenerative medicine.

Moya IM, Halder G.

Nat Rev Mol Cell Biol. 2019 Apr;20(4):211-226. doi: 10.1038/s41580-018-0086-y. Review.

PMID:
30546055
8.

Targeting the Hippo Signaling Pathway for Tissue Regeneration and Cancer Therapy.

Juan WC, Hong W.

Genes (Basel). 2016 Aug 30;7(9). pii: E55. doi: 10.3390/genes7090055. Review.

9.

The Hippo pathway effectors TAZ/YAP regulate dicer expression and microRNA biogenesis through Let-7.

Chaulk SG, Lattanzi VJ, Hiemer SE, Fahlman RP, Varelas X.

J Biol Chem. 2014 Jan 24;289(4):1886-91. doi: 10.1074/jbc.C113.529362. Epub 2013 Dec 9.

10.

Atheroprotective laminar flow inhibits Hippo pathway effector YAP in endothelial cells.

Xu S, Koroleva M, Yin M, Jin ZG.

Transl Res. 2016 Oct;176:18-28.e2. doi: 10.1016/j.trsl.2016.05.003. Epub 2016 May 26.

11.

Upregulation of Yes-associated protein and transcriptional co-activator with PDZ-binding motif influences the behavior of LOVO human colon adenocarcinoma cells.

Li Y, Li L, Zhu M, Ye L, Yang Q.

Exp Ther Med. 2017 Oct;14(4):3831-3835. doi: 10.3892/etm.2017.4962. Epub 2017 Aug 18.

12.

Stearoyl-CoA-desaturase 1 regulates lung cancer stemness via stabilization and nuclear localization of YAP/TAZ.

Noto A, De Vitis C, Pisanu ME, Roscilli G, Ricci G, Catizone A, Sorrentino G, Chianese G, Taglialatela-Scafati O, Trisciuoglio D, Del Bufalo D, Di Martile M, Di Napoli A, Ruco L, Costantini S, Jakopin Z, Budillon A, Melino G, Del Sal G, Ciliberto G, Mancini R.

Oncogene. 2017 Aug 10;36(32):4573-4584. doi: 10.1038/onc.2017.75. Epub 2017 Apr 3. Erratum in: Oncogene. 2017 Jun 19;:.

PMID:
28368399
13.

Relationship between Keloid Formation and YAP/TAZ Signaling.

Aramaki-Hattori N, Okabe K, Hamada M, Takato T, Kishi K.

Plast Reconstr Surg Glob Open. 2017 Jun 13;5(6):e1357. doi: 10.1097/GOX.0000000000001357. eCollection 2017 Jun.

14.

YAP/TAZ: a promising target for squamous cell carcinoma treatment.

Dong X, Meng L, Liu P, Ji R, Su X, Xin Y, Jiang X.

Cancer Manag Res. 2019 Jul 8;11:6245-6252. doi: 10.2147/CMAR.S197921. eCollection 2019.

15.

New insights into YAP/TAZ nucleo-cytoplasmic shuttling: new cancer therapeutic opportunities?

Shreberk-Shaked M, Oren M.

Mol Oncol. 2019 Jun;13(6):1335-1341. doi: 10.1002/1878-0261.12498. Epub 2019 May 17. Review.

16.

Hypoxic conditions differentially regulate TAZ and YAP in cancer cells.

Yan L, Cai Q, Xu Y.

Arch Biochem Biophys. 2014 Nov 15;562:31-6. doi: 10.1016/j.abb.2014.07.024. Epub 2014 Jul 29.

17.

Reciprocal regulation of YAP/TAZ by the Hippo pathway and the Small GTPase pathway.

Jang JW, Kim MK, Bae SC.

Small GTPases. 2018 Apr 20:1-9. doi: 10.1080/21541248.2018.1435986. [Epub ahead of print]

PMID:
29457552
18.

A YAP/TAZ-induced feedback mechanism regulates Hippo pathway homeostasis.

Moroishi T, Park HW, Qin B, Chen Q, Meng Z, Plouffe SW, Taniguchi K, Yu FX, Karin M, Pan D, Guan KL.

Genes Dev. 2015 Jun 15;29(12):1271-84. doi: 10.1101/gad.262816.115.

19.

SRC tyrosine kinase activates the YAP/TAZ axis and thereby drives tumor growth and metastasis.

Lamar JM, Xiao Y, Norton E, Jiang ZG, Gerhard GM, Kooner S, Warren JSA, Hynes RO.

J Biol Chem. 2019 Feb 15;294(7):2302-2317. doi: 10.1074/jbc.RA118.004364. Epub 2018 Dec 17.

20.

TNF-α-Induced YAP/TAZ Activity Mediates Leukocyte-Endothelial Adhesion by Regulating VCAM1 Expression in Endothelial Cells.

Choi HJ, Kim NE, Kim BM, Seo M, Heo JH.

Int J Mol Sci. 2018 Nov 1;19(11). pii: E3428. doi: 10.3390/ijms19113428.

Supplemental Content

Support Center